Skip to main content
+91 99977 76330

What Is Acute Myeloid Leukemia (AML)?

Written by Dr. Vrundali Kannoth

7 min read

What Is Acute Myeloid Leukemia (AML)?
  • AML is a fast-growing blood cancer that begins in the bone marrow, where new blood cells are made.
  • In AML, immature myeloid cells (blasts) multiply uncontrollably, crowding out healthy blood cells and interfering with the production of red cells, white cells, and platelets.
  • Because these abnormal cells grow quickly, AML can progress rapidly and needs prompt diagnosis and treatment.

What Causes AML?

  • AML develops when blood-forming cells in the bone marrow gain genetic mutations that let them grow and survive abnormally.
  • These mutations are usually acquired during life, not inherited.
  • Risk factors include older age, previous chemotherapy or radiation, certain blood disorders, chemical exposures, and some inherited gene syndromes, but often there is no clear cause.

Common Symptoms of AML

  • Symptoms result from the disruption of normal blood cell production, including:
    • Fatigue and weakness (from low red blood cells/anemia)
    • Frequent infections and fevers (from low/abnormal white blood cells)
    • Easy bruising or bleeding, bleeding gums, or nosebleeds (from low platelets)
    • Shortness of breath, dizziness, pale skin
    • Other symptoms: bone pain, weight loss, swollen lymph nodes or spleen
  • Persistent or unexplained symptoms—especially with abnormal blood counts—should prompt medical evaluation.

How Is AML Diagnosed?

  • Blood tests:Complete blood count (CBC) and blood smear can reveal abnormal or low blood cell counts and presence of blasts.
  • Bone marrow tests:Aspiration and biopsy confirm AML by checking for a high number of blasts (usually 20% or more).
  • Cytogenetic and molecular testing:Chromosome analysis and molecular tests identify gene mutations and chromosomal changes that help classify AML and guide treatment.

Genetic and Molecular Testing in AML

  • DNA and RNA analysis from leukemia cells can uncover mutations and gene fusions, helping define disease subtypes and identify options for targeted therapy.
  • Testing may include mutation panels, fusion detection, and next-generation sequencing (NGS).
  • These findings support precision medicine—customizing treatment to the patient’s unique genetic profile.

AML Subtypes and Genetic Changes

  • AML is diverse, with various genetic abnormalities driving different subtypes.
  • Some cases involve specific gene mutations (like FLT3, NPM1, IDH1/2), others involve chromosome changes or gene fusions (like RUNX1-RUNX1T1).
  • This genetic diversity means patients can have very different disease courses and treatment plans.

How Is AML Treated?

  • Chemotherapy:Mainstay treatment to kill leukemia cells and restore normal blood cell production; typically involves an initial phase (induction) followed by consolidation.
  • Targeted Therapy:Used if specific mutations (FLT3, IDH1, IDH2) are present.
  • Stem Cell Transplant:May be recommended for fit patients with higher-risk disease; carries risks but can improve long-term outcomes.
  • Supportive Care:Includes antibiotics, antifungals, transfusions, growth factors, and monitoring to manage complications.

Planning Treatment in AML

  • Treatment decisions are based on age, health, AML subtype, genetic results, prior treatments, and response to initial therapy.
  • Molecular and cytogenetic findings are key to selecting the best approach and may point to clinical trial options.

Monitoring and Minimal Residual Disease (MRD)

  • MRD refers to small numbers of leukemia cells that remain after treatment, which can be detected by sensitive tests (flow cytometry, PCR, NGS).
  • MRD testing helps evaluate response and relapse risk.

AML Prognosis

  • Outlook varies and depends on disease subtype, genetic features, age, health, and response to treatment.
  • Younger, healthier patients with favorable genetic changes generally do better than older or frail patients with high-risk genetics.
  • Survival rates and treatment success vary—prognosis should always be discussed with your care team.

Key Takeaways AML is a rapidly progressing blood cancer that disrupts normal blood cell production. Signs include fatigue, infection, fever, easy bruising/bleeding, and shortness of breath. Diagnosis is based on blood tests, bone marrow exams, and advanced genetic/molecular testing. Treatment options include chemotherapy, targeted therapy, stem cell transplant, and supportive care—tailored to the individual. MRD testing can track treatment response. Prognosis depends on many factors; always review your individual case with a specialist.

Common questions

Can’t find your answer?

Our care team will talk it through with you.

+91 99977 76330
Common symptoms:

Fatigue, infections, fever, easy bruising/bleeding, shortness of breath.

Diagnosis:

Blood tests, bone marrow biopsy, genetic/molecular testing.

Genetic tests used:

Cytogenetics, mutation/fusion testing, NGS panels.

Treatment options:

Chemotherapy, targeted therapy, stem cell transplant, supportive care.

Can AML be monitored with MRD testing?

Yes, using flow cytometry, PCR, or NGS to detect residual disease and relapse risk.

Can’t find your answer?

Our care team will talk it through with you.

+91 99977 76330
Cancer nutrition supplements
Nutritional supplements curated by oncologists
A platform for cancer nutrition.
Clinically guided. Built for care.